To Get Our Money’s Worth in Healthcare, We Need to Collaborate

In a commentary for Modern Healthcare, IVI Director of Scientific Communications, Mark Linthicum, emphasizes that the healthcare system needs to embrace collaboration to find consensus in the way we measure and pay for health care value. Read the full article here.

2018-01-22T22:29:16+00:00 January 22nd, 2018|Viewpoints|

Well-Informed Patients Play a Key Role in Value-Based Care

In a commentary for Morning Consult, Virginia Ladd, President and Executive Director of the American Autoimmune Related Diseases Association (AARDA), emphasizes how critical it is that the patient perspective be front and center in discussions about how we measure and pay for value. Read the full article here.

2018-01-18T05:19:24+00:00 January 12th, 2018|Viewpoints|

Putting More Value Into Biopharmaceutical Value Assessments

In a commentary for the Health Affairs Blog, Rena M. Conti, PhD, and IVI Executive Director, Darius Lakdawalla, argue that advancing the science of value assessment requires new assessment tools that are transparent and incorporate the perspectives of patients and insurance plan enrollees. Read the full article here.

2018-02-23T20:39:07+00:00 January 4th, 2018|Viewpoints|

An Open-Source Consensus-Based Approach to Value Assessment

In a commentary for the Health Affairs Blog, IVI's Jeroen Jansen, Devin Incerti, and Mark Linthicum argue that, in order to move toward consensus on value assessment, the process for defining and measuring value must be transparent, collaborative, and iterative. IVI is taking the first steps towards consensus with the development of the Open-Source Value Project. [...]

2017-12-15T23:12:42+00:00 December 15th, 2017|Viewpoints|

IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform

Mark Linthicum makes the case that value-based spending should be the focus of health care reform efforts in Washington, D.C. On September 13th health care stakeholders came together at the National Press Club to discuss better approaches to measuring value. Read Full Article Here

2017-11-11T01:18:31+00:00 September 20th, 2017|Viewpoints|

Shafrin Defines Precision Medicine for U.S. News and World Report

In a new commentary for U.S. News and World Report, Jason Shafrin defines and elaborates on the field of precision medicine. Jason, IVI's Director of Research, illustrates how the United States is moving headlong into this new treatment approach. He notes some of the challenges while also emphasizing the unique hope precision medicine brings through [...]

2017-11-11T01:22:04+00:00 August 25th, 2017|Viewpoints|

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative's latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible [...]

2017-11-09T02:27:26+00:00 July 13th, 2017|Viewpoints|

Sachs Summarizes Recent HELP Committee Meeting: The Elephant in the Room

In the latest post on the the IVI-sponsored Health Affairs blog series, Rachel Sachs summarizes the recent Senate Health, Education, Labor & Pensions (HELP) Committee meeting. Organized to address the drug delivery system and how it influences what patients pay, the meeting quickly shifted to a partisan blasting of the secretive process by which Republicans [...]

2017-07-14T05:22:13+00:00 June 20th, 2017|Viewpoints|

Lietzan Examines SCOTUS Ruling on Biosimilars

In the latest post on the the IVI-sponsored Health Affairs blog series, Drugs and Medical Innovation, Erica Lietzan takes a look at the recent Supreme Court ruling on Sandoz v. Amgen, examining premarket patent litigation, patent resolution process, state law influence, and the impact of the SCOTUS ruling itself. Read the full article here.

2017-07-14T05:22:20+00:00 June 19th, 2017|Viewpoints|

IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight

In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is [...]

2017-07-18T22:26:51+00:00 June 19th, 2017|Viewpoints|